ASND
Ascendis A/SFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Successful clinical readouts, clear regulatory paths, or a strategic partnership could drive material re-rating; commercial execution on approved programs would further de-risk the story.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -3.6.
What can break
Clinical trial failure or negative readout
Momentum
55
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $28.16 · Bull $46.08 · Bear $12.80
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-10-02 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $284.90
Why
Momentum55 · Δ7d -3.6
Value41 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
55
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.6
Δ21d
+7.8
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 54.8 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$13.65B
Beta
0.43
Shares Out
61.7M
P/E (TTM) · Derived
-52.1
P/S (TTM)
17.35
P/FCF (TTM) · Derived
-109.04
Rev YoY
+269.4%
EPS YoY
+41.8%
Gross Margin
+86.8%
Op Margin
-22.5%
Net Debt
$321.42M
Current Ratio
1.03
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology